research centers


Search results: Found 3

Listing 1 - 3 of 3
Sort by

Article
Evaluation of Pulmonary Artery Pressure in End Stage Renal Disease in Babylon Province

Authors: Hassanain Mohammed Saeed Abdullamir --- Ali Jasim Mhemeed Al-Sultani --- Ahlam Kadhim Abood Al-Hamdany
Journal: Medical Journal of Babylon مجلة بابل الطبية ISSN: 1812156X 23126760 Year: 2016 Volume: 13 Issue: 2 Pages: 459 -467
Publisher: Babylon University جامعة بابل

Loading...
Loading...
Abstract

Pulmonary hypertension (PHT) is a serious cardiac complication and highly prevalent in end-stage renal disease (ESRD).The aim of this study is to evaluation the PHT in ESRD and its relation with left and right side echocardiographic cardiac indices. Fifty patients with ESRD were included in the study. Echocardiography was used to evaluate systolic pulmonary artery pressure (sPAP),Tricuspid annular plane systolic excursion (TAPSE), cardiac output (CO),left ventricular mass(LVM). Cardiac index (CI) and left ventricular mass index(LVMI) were obtained by dividing CO and LVM onbody surface area (BSA).The results are : Percentage of PHT in ESRD is about 50% . Percentage of abnormal LVM , LVMI ,and TAPSE are: 76% (167-498 g), 78.9% (109-287g/m2),and 18.4% (1.1-1.8 cm) respectively. Correlation study between PHT and TAPSE showed statistically significant negative correlation (r = -0.38, p < 0.05). Correlation studies of PHT with LVM and LVMI were weak correlation and statically non-significant, but technically showed a positive correlation (r = 0.109, 0.094) respectively. The conclusion: pulmonary hypertension is extraordinary common Among hemodialysis patients and volume overload have played an important role in the mechanism of pulmonary hypertension in end stage renal disease .

Keywords

PHT --- ESRD --- LVM --- LVMI.


Article
Effects of Dose Amount for Antiepileptic Drugs on Lipid Profile of Male Rats (Rattus Norvegicus).
تأثير كمية الجرعة للأدوية المضادة للصرع في مستوى الدهون لذكور الجرذان المختبرية

Author: Abbas Mohsin Abbas عباس محسن عباس
Journal: JOURNAL OF THI-QAR SCIENCE مجلة علوم ذي قار ISSN: 19918690 Year: 2017 Volume: 6 Issue: 2 Pages: 90-95
Publisher: Thi-Qar University جامعة ذي قار

Loading...
Loading...
Abstract

The present study aimd to estimate the changes in lipid profile depend on dosage amount of two AEDs ,Phenytoin (PHT) and Carbamazepine (CBZ) , and make a comparison between them in rats. A 30 healthy male Wistar rats (150-200 g) ( subdivide to five groups ) first group was control , the second and third groups received (50 mgkg and 100 mgkg) of Phenytoin respectively, fourth and fifth groups received (25 mg/kg and 50 mg/kg) of Carbamazepine respectively. Serum total cholesterol (TC), triglycerides (TGs) and High-density lipoprotein (HDL) levels were measured after 20 days period of treating, Low-density lipoprotein (LDL) and Very low-density lipoprotein (VLDL) was calculated also. Our data revealed that, the administration of PHT (50 mgkg) and CBZ (25 mgkg) didn’t affect serum lipid profile significantly compared to control group in male rats except the levels of VLDL in CBZ (25 mgkg) group which increased significantly (p-value <0.05) compared to control group, on the other hand we found that the administration of double dose (PHT 100 mgkg and CBZ 50 mg/kg) in group3 and group5 respectively caused a significant increase in TC, TGs, LDL and VLVL in both groups compare to control group. According to our results we conclude that the doubling the dose of CBZ and PHT cause an increase in cholesterol, TGs, LDL and VLDL and switching from CBZ and PHT to another drugs or decrease the dosage could contributes to avoid effects on the lipid metabolism profile of patients with chronic epilepsy.

تهدف الدراسة الحالية إلى تقدير التغييرات في مستويات الكوليسترول الكلي والبروتينات الدهنية اعتمادا على كمية الجرعة لاثنين من ادوية الصرع، الفينيتوين (PHT) و الكاربامازيبين (CBZ)، وإجراء مقارنة بينهما. (30) من ذكور الجرذان المختبرية (150-200غم) (قسمت إلى خمس مجموعات) وكانت المجموعة الأولى مجموعة السيطرة، جرعت المجموعتين الثانية والثالثة بــ(50 ملغ كغ و 100 ملغ كغم) من الفينيتوين على التوالي , المجموعة الرابعة و الخامسة تم تجريعها بـ(25 ملغ كغ و 50 ملغم كغم) من كاربامازيبين على التوالي. و بعد فترة 20 يوما من التجريع اليومي تم قياس الكولسترول الكلي (TC)، و الكليسيريدات الثلاثية (TGs) والبروتينات الدهنية عالية الكثافة (HDL) ، اما البروتينات الدهنية منخفضة الكثافة (LDL) و البروتينات الدهنية ذات الكثافة الواطئة جدا (VLDL) تم حسابها من خلال معادلة خاصة. أظهرت نتائج الدراسة أن الجرعة (50 ملغ كغم) فينتوين و ) 25ملغ كغم) كاربامازيبين لم يؤثر على مستوى الدهون في الدم بشكل ملحوظ مقارنة مع مجموعة السيطرة في ذكور الجرذان باستثناء مستويات VLDL في المجموعة التي عوملت بـ(25 ملغ كغم) كاربامازيبين ارتفعت معنويا عند مستوى معنوية (p-value <0.05) مقارنة بمجموعة السيطرة، من ناحية أخرى وجدنا أن اعطاء جرعة مضاعفة من العلاجين تسبب في زيادة في مستويات TC، TGs، LDL وVLVL في كلا المجموعتين مقارنة بمجموعة عند مستوى معــــــنوية (p-value <0.05). وفقا لنتائج الدراسة الحالية، نستنتج أن مضاعفة جرعة الفينتوين و الكاربامازيبين سبب زيادة في الكولسترول، TGs، LDL وVLDL , وان التحول من هذين العلاجين الى ادوية أخرى او تقليل الجرعة يمكن ان يساعد في تقليل اثارهما الجانبية.

Keywords

AEDs --- CBZ --- PHT --- lipid profile --- Cholesterol --- TGs --- HDL --- LDL --- VLDL.


Article
Platelets Count As A Predictor For Portal Hypertension in Patients With Ascites

Authors: Sadiq J. Almuhana --- Ali Kadim Radi --- Lath Abdulhussein --- Abbas Al-dabbagh
Journal: Medical Journal of Babylon مجلة بابل الطبية ISSN: 1812156X 23126760 Year: 2014 Volume: 11 Issue: 4 Pages: 851-857
Publisher: Babylon University جامعة بابل

Loading...
Loading...
Abstract

Background: Serum Ascetic Albumin Gradient is a good biochemical marker and a better discriminator of portal hypertension. Patients with gradients of >1.1 g/dL have portal hypertension, while those with gradients of <1.1 g/dL do not, with accuracy rate 97% and sensitivity of 100%. Thrombocytopenia is a frequent and challenging clinical disorder in patients with portal hypertension. The most sensitive and specific laboratory finding suggestive of cirrhosis in the setting of chronic liver disease is a low platelet count (<150×109/L), which occurs as a result of portal hypertension and hypersplenism. Aim of Study:To predict the presence of portal hypertension in patient with ascites by measuring the platelets count.Patients and Methods: Fifty patients with ascites were sent for complete blood picture, serum albumin, echo study, abdominal ultrasound and albumin in ascites fluid along with thorough medical history and examination. we calculate the SAAG for all patients and classified into two groups , the first has SAAG> 1.1 g/dl and considered to have portal hypertension, the second has SAAG <1.1 g/dl. Results: In this study, 50 patients with ascites their ages ranges from (34-60) years ,25 of them had SAAG more than 1.1g/dl , 20 of them had platelet count <150×109/L. while 25 patients with SAAG less than 1.1g/dl, 7 of them had platelet count <150×109/L. this indicate significant correlation between low platelet count and portal hypertension(p value 0.0002)(the measured sensitivity=84%, specificity=76%, P.P.V=77%, N.P.V=82%) . Another significant correlation was seen between splenomegaly detected by U/S and portal hypertension, 25 patient had SAAG more than 1.1g/dl, of them 12 had splenomegaly ( p value 0.00039)(the measured sensitivity=48%, specificity=96%, P.P.V=92%, N.P.V=64%)Conclusion: Thrombocytopenia in patient with ascites may predict portal hypertension.

Listing 1 - 3 of 3
Sort by
Narrow your search

Resource type

article (3)


Language

English (3)


Year
From To Submit

2017 (1)

2016 (1)

2014 (1)